Clinical Trial Update: Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is evaluating pharmacokinetic-guided dosing of hydroxyurea in patients with moderate to severe sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Yves Pastore | Conditions: Sickle Cell Disease (SCD) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING